New Research for treatment of Dry Advanced Macular Degeneration

LumiThera LT-300 Device For Treating Dry Advanced Macular Degeneration Granted CE Mark

SEATTLE, June 22, 2018 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company focused on developing non-invasive Photobiomodulation (PBM) therapies for ocular disorders and disease, announced CE Mark Certification for the European Union (EU) for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System.
The “CE” mark is the abbreviation for Conformité Européenne, meaning European Conformity. CE marking is a certification that indicates conformity with health, safety, and environmental protection directives for products sold within the European Economic Area (EEA).
“The CE mark allows LumiThera to begin commercialization throughout the 28 EU member states and coincides with the initiation of the LIGHTSITE II Clinical Study in select European sites in the upcoming months,” stated Clark Tedford, Ph.D., LumiThera President and CEO. “We are excited to be able to offer a safe and effective early stage clinical intervention for patients with dry AMD.”
“It is very exciting to see the development of PBM treatment for dry AMD patients,” stated Samuel Markowitz, M.D., Department of Ophthalmology and Vision Sciences, University of Toronto. “These patients have limited options and losing their central vision is horribly debilitating to their quality of life. The previous LIGHTSITE I Clinical Studies demonstrated that PBM therapy was most beneficial in early stage dry AMD patients. It was also determined that retreatments at scheduled intervals will be needed to maintain clinical benefits.”
“PBM may change the way we think about treating dry AMD,” says Dr. Robert Devenyi, Ophthalmologist-in-Chief and Director of Retinal Services, UHN, University of Toronto. “Until now we just waited and watched the patients lose vision with limited therapeutic options. Now we may have a treatment that can target improvement in visual outcomes and reduce a key component of the pathology. The next step is to confirm the early results in the multi-center LIGHTSITE II trial and work with ophthalmology medical community in establishing best treatment practices.
Read more at the Company’s website at: www.lumithera.com
Source: LumiThera
Image: LumiThera

On